Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

  title={Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm},
  author={Daniel Perkins and Jerome Sarris and Susan Lee Rossell and Yvonne Ann Bonomo and David Forbes and Christopher G. Davey and Daniel Hoyer and Colleen K. Loo and Greg Murray and Sean D Hood and Violeta Schubert and Nicole Leite Galv{\~a}o-Coelho and Meaghen O'Donnell and Olivia Carter and Paul Liknaitzky and Martin Williams and Dan J Siskind and David G. Penington and Michael Berk and David Jonathan Castle},
  journal={Australian \& New Zealand Journal of Psychiatry},
  pages={1127 - 1133}
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on Psychedelics’ recently released by the Royal Australian and New Zealand College of Psychiatrists and note… 

Figures from this paper

The frontiers of new psychedelic therapies: A survey of sociological themes and issues

A sociological lens on clinical psychedelic therapies is offered and three areas of sociological interest are critically examined: the of role advocacy in the advancement of scientific research and the destigmatisation of psychedelics; issues related to the medicalisation and pharmaceuticalisation; and integration into healthcare systems.

Why was early therapeutic research on psychedelic drugs abandoned?

  • W. Hall
  • Medicine, Psychology
    Psychological Medicine
  • 2021
The demise of psychedelic drug research was not solely due to the ‘War on Drugs’, but was hastened by tighter regulation of pharmaceutical research, the failure of controlled clinical trials to live up to the claims of psychedelic advocates, and the pharmaceutical industry's lack of interest in funding clinical trials.

A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders

Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support, and both agents were well tolerated in supervised trials.

Natural and Experimental Evidence Drives Marmosets for Research on Psychiatric Disorders Related to Stress

The experimental evidence obtained so far is reviewed and the extension of the marmoset as an animal model for depression is discussed, which makes this species a potential animal model to study disorders related to social stress.

Biomarkers for Deep Brain Stimulation in Animal Models of Depression.

DBS is a promising therapeutic modality for treatment-resistant depression and electrophysiological and biochemical markers appear to offer the greatest potential as biomarkers for depression, but additional preclinical and clinical studies with a focus on identifying reliable, safe, and effective biomarkers are warranted.

Disruptive innovation in psychiatry

  • J. Sarris
  • Psychology
    Annals of the New York Academy of Sciences
  • 2022
Disruptive innovation is a cornerstone of various disciplines, particularly in the business world, where paradigm‐altering approaches are often lauded. As a construct, disruptive psychiatry can be

Application of machine learning and complex network measures to an EEG dataset from DMT experiments

There is a growing interest in the medical use of psychedelic substances as preliminary studies using them for psychiatric disorders have shown positive results. In particularly, one of these

Review of ‘ Transtheoretical model of harm reduction and integration for the use of psychedelics ’ ( Gorman et al . , 2021 )

The Transtheoretical Model of Harm Reduction and Integration (PHRI) proposes an approach that incorporates principles of harm reduction psychotherapy, psychedelicassisted therapy, mindfulness-based



Psychedelics and Psychedelic-Assisted Psychotherapy.

The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising, and the database for MDMA and psilocybin is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders.

Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis

This meta-analysis shows that psychedelic treatments were safe and could contribute to a rapid improvement of depressive symptoms.

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews

Results are promising, several studies were open label, and only few were RCTs, and most had small sample sizes and a short duration, but long-term studies are lacking.

Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.

The strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy

Other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors' ongoing study exploring the potential role for MDMA-assisted psychotherapy to treat alcohol use disorder.

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

It is demonstrated how qualitative research of psychedelic treatments can contribute to distinguishing specific features of specific substances, and carry otherwise undiscovered implications for the treatment of specific psychiatric disorders.

Dimethyltryptamine: Endogenous Role and Therapeutic Potential

While the role of endogenous DMT remains unclear, ayahuasca has promising results in anxiety, depression and substance dependence, and it is crucial to conduct further research aimed at developing new treatments for psychiatric disorders.